Opiant Pharmaceuticals is a specialty pharmaceutical company developing treatments for substance use, addictive and eating disorders.
Quote | Opiant Pharmaceuticals Inc. (NASDAQ:OPNT)
Last: | $20.65 |
---|---|
Change Percent: | -1.1% |
Open: | $20.8765 |
Close: | $20.65 |
High: | $21 |
Low: | $20.5 |
Volume: | 562,778 |
Last Trade Date Time: | 03/01/2023 03:00:00 am |
News | Opiant Pharmaceuticals Inc. (NASDAQ:OPNT)
Summary Horizon Therapeutics Public Limited Company is a $25 billion biotech that's being acquired by Amgen Inc. The FTC has issued a 2nd request following a letter by Senator Elizabeth Warren. Warren raises a number of important issues but few that pertain specifically to this deal...
Summary Opiant appears on track to be acquired for $20/share and offers various Contingent Value Rights (CVRs) linked to a potential drug launch. The drug helps with opioid reversal after an overdose and has a scheduled FDA review date of May 2023. If certain revenue targets are hit...
Message Board Posts | Opiant Pharmaceuticals Inc. (NASDAQ:OPNT)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $OPNT News Article - OPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale | whytestocks | investorshangout | 11/14/2022 6:25:51 PM |
whytestocks: $OPNT News Article - Party City Layoffs 2022: What to Know About the PRTY Job Cuts | whytestocks | investorshangout | 11/14/2022 4:35:48 PM |
whytestocks: $OPNT News Article - SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of | whytestocks | investorshangout | 11/14/2022 3:15:47 PM |
whytestocks: $OPNT News Article - Indivior PLC to Acquire Opiant Pharmaceuticals | whytestocks | investorshangout | 11/14/2022 3:01:56 PM |
whytestocks: $OPNT News Article - Indivior To Acquire Opiant Pharmaceuticals | whytestocks | investorshangout | 11/14/2022 2:55:47 PM |
News, Short Squeeze, Breakout and More Instantly...
Opiant Pharmaceuticals Inc. Company Name:
OPNT Stock Symbol:
NASDAQ Market:
CFIUS clearance represents the final required regulatory approval to complete the proposed merger Completion remains subject to the approval of Opiant stockholders; a special stockholder meeting to approve the acquisition will be held on March 1, 2023 Indivior and Opiant c...
SANTA MONICA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals Inc. (NASDAQ: OPNT) announced today the expiration of the waiting period under the United States (U.S.) Hart-Scott-Rodino Act of 1976, as amended (HSR Act), with respect to the previously announced agreement for Opiant...
FDA sets PDUFA date of May 22, 2023 SANTA MONICA, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for...